Skip to content

Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)

Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02559804
Acronym
NB-SCI
Enrollment
150
Registered
2015-09-24
Start date
2014-05-31
Completion date
2029-05-31
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastic Tumors

Brief summary

To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes

Detailed description

Multi-centre, observational, prospective study registry. About 15% of patients with peripheral neuroblastic tumour present with extradural SCI, of whom approximately 60% are symptomatic. Since SCI may progress to irreversible paraplegia, early diagnosis and prompt treatment is of critical importance.1-3 The treatment options include chemotherapy, neurosurgical decompression and radiation therapy. All may relieve epidural compression, but there is no consensus on which to use first in the individual patient. However, the choice of the treatment could be relevant in the perspective of reducing to the minimum the risk of long-term sequelae.4 Guidelines for the diagnostic work-up and treatment of SCI for International Society of Paediatric Oncology European Neuroblastoma (SIOPEN) neuroblastoma patients were already available in the guidelines for the treatment of patients with localized resectable neuroblastoma and analysis of prognostic factors (LNESG1 Protocol), back in 1994,5 although it is unknown how they were applied in the SIOPEN Centres. These guidelines have been reformulated in occasion of the recently activated European Low and Intermediate risk Neuroblastoma (LINES Protocol). There are few publications addressing the diagnosis and treatment of SCI; most are retrospective studies, case reports, or reviews that may be affected by reporting bias.1-9 Therefore new guidelines could be designed based on the information derived from a prospective data collection of newly diagnosed patients. For this study Spinal Canal Involvement (SCI) is defined when, referring to an axial plane of the spinal cord MRI scan (Figure 1), the tumour extends into the vertebral canal and goes beyond a mentally drown ellipsoid (red circle) passing through the cortical bone of both anterior and posterior arches of the vertebra. This involvement is called intraspinal or, better, intracanal. Patient data to be collected and included in the corresponding Forms 1. work-up at diagnosis, including radiology report (Computed Tomography or Magnetic Resonance Imaging) 2. treatment administered 3. response to treatment, including radiology report 4. follow-up 5. outcome

Interventions

OTHERsurvival and late effects

survival and late effects

Sponsors

Istituto Giannina Gaslini
CollaboratorOTHER
Associazione Italiana Ematologia Oncologia Pediatrica
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression) * No previous chemotherapy, except steroids, in the last 6 months * Age \<18 years * Minimal planned follow-up of 5 years * Parent/patient written informed consent (Appendix 1(A,B,C))

Exclusion criteria

* Invasion of intervertebral foramina only

Design outcomes

Primary

MeasureTime frameDescription
prevalence of neurologic consequencesfor 5 yearsAmerican Spinal Injury Association ASIA impairment scale
prevalence of orthopedic consequencesfor 5 yearsusing Common Terminology Criteria for Adverse Events v. 4.0
prevalence of painfor 5 yearsusing Face, Legs, Activity, Cry, Consolability scale (FLACC scale)

Secondary

MeasureTime frameDescription
relapse or second tumour5 yearsevent free survival
survival5 yearsoverall survival

Countries

Italy

Contacts

Primary ContactRiccardo Haupt, MD
riccardohaupt@ospedale-gaslini.ge.it01056363462
Backup Contacttiziana landi
segreteria@aieop.org051/2144667

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026